Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.60 |
| ▸ | DCK | P27707 | 15/20 | 0.44 |
| ▸ | POLG | P54098 | 1/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.37 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8088509 | 0.81 | ALB (0.68) | ALBDCKPOLGCACNA1FLMNA | |
| SCHEMBL599406 | 0.80 | ALB (0.56) | ALBDCKPOLG | |
| SCHEMBL599407 | 0.80 | ALB (0.56) | ALBDCKPOLG | |
| SCHEMBL27527424 | 0.79 | ALB (0.69) | ALBDCKPOLGCACNA1FLMNA | |
| SCHEMBL6404292 | 0.78 | ALB (0.64) | ALBDCKPOLGCACNA1FLMNA | |
| SCHEMBL9122186 | 0.77 | ALB (0.54) | ALBDCKPOLG | |
| SCHEMBL9067244 | 0.76 | ALB (0.59) | ALBDCKPOLGCACNA1FLMNA | |
| SCHEMBL7124283 | 0.76 | ALB (0.59) | ALBDCKPOLGCACNA1FLMNA | |
| SCHEMBL9067540 | 0.76 | ALB (0.59) | ALBDCKPOLGCACNA1FLMNA | |
| Phosphoric Acid SCHEMBL599685 | 0.75 | ALB (0.52) | ALBDCKPOLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | ALB 1488/4885DCK 542/4885POLG 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.